(SIGA) SIGA Technologies - Overview

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US8269171067

Stock: Smallpox Antiviral, Oral Capsule, IV Formulation

Total Rating 42

Risk 80

Buy Signal -0.75

Drug Manufacturers - Specialty & Generic -1.8
Pharmaceuticals +4.0

Market Cap: 415m
Avg Trading Vol: 2.94M USD

ATR: 4.75%
Peers RS (IBD): 30.2

Risk 5d forecast
Volatility	57.1%
Relative Tail Risk	-11.3%

Reward TTM
Sharpe Ratio	0.35
Alpha	-7.55

Character TTM
Beta	0.882
Beta Downside	1.523

Drawdowns 3y
Max DD	56.39%
CAGR/Max DD	0.17

EPS (Earnings per Share)

EPS CAGR: 3.13%
EPS Trend: 7.3%

Last SUE: 0.00
Qual. Beats: 0

Revenue

Rev. CAGR: -63.55%
Rev. Trend: -24.8%

Last SUE: 0.44
Qual. Beats: 0

Description: SIGA SIGA Technologies March 01, 2026

SIGA Technologies, Inc. (NASDAQ: SIGA) is a commercial-stage biotech focused on the U.S. health-security market, best known for its FDA-approved antiviral TPOXX, the only licensed treatment for smallpox.

As of Q4 2025, SIGA reported $84 million in total revenue, with TPOXX contributing roughly 68% and a cash runway of $210 million, giving it a solid liquidity position amid ongoing government contracts. The company’s R&D expense has risen 12% YoY, reflecting expansion into additional orthopoxvirus indications, while the broader pharmaceuticals sector benefits from a 4.5% annual increase in U.S. biodefense spending, a key economic driver for SIGA’s pipeline.

For a deeper quantitative view, you might explore ValueRay’s analyst tools.

Headlines to watch out for

Government procurement contracts for TPOXX drive revenue growth
Smallpox outbreak potential impacts TPOXX demand
Regulatory approval for TPOXX in new markets expands sales
Biodefense spending policies influence contract awards

Piotroski VR‑10 (Strict, 0-10) 5.5

Net Income: 74.5m TTM > 0 and > 6% of Revenue
FCF/TA: 0.50 > 0.02 and ΔFCF/TA 13.64 > 1.0
NWC/Revenue: 117.8% < 20% (prev 91.17%; Δ 26.63% < -1%)
CFO/TA 0.50 > 3% & CFO 116.6m > Net Income 74.5m
Net Debt (-171.0m) to EBITDA (94.3m): -1.81 < 3
Current Ratio: 9.17 > 1.5 & < 3
Outstanding Shares: last quarter (71.6m) vs 12m ago -0.23% < -2%
Gross Margin: 76.29% > 18% (prev 0.78%; Δ 7.55k % > 0.5%)
Asset Turnover: 80.69% > 50% (prev 88.93%; Δ -8.24% > 0%)
Interest Coverage Ratio: -29.47 > 6 (EBITDA TTM 94.3m / Interest Expense TTM -3.18m)

Altman Z'' 6.76

A: 0.88 (Total Current Assets 227.7m - Total Current Liabilities 24.8m) / Total Assets 231.6m
B: -0.16 (Retained Earnings -37.6m / Total Assets 231.6m)
C: 0.44 (EBIT TTM 93.7m / Avg Total Assets 213.5m)
D: -1.34 (Book Value of Equity -37.6m / Total Liabilities 28.1m)
Altman-Z'' Score: 6.76 = AAA

Beneish M -4.00

DSRI: 0.21 (Receivables 2.49m/12.1m, Revenue 172.2m/173.7m)
GMI: 1.03 (GM 76.29% / 78.34%)
AQI: 0.17 (AQ_t 0.01 / AQ_t-1 0.07)
SGI: 0.99 (Revenue 172.2m / 173.7m)
TATA: -0.18 (NI 74.5m - CFO 116.6m) / TA 231.6m)
Beneish M-Score: -4.34 (Cap -4..+1) = AAA

What is the price of SIGA shares?

As of March 12, 2026, the stock is trading at USD 5.65 with a total of 933,688 shares traded.
Over the past week, the price has changed by -14.05%, over one month by -17.55%, over three months by -16.03% and over the past year by +7.97%.

Is SIGA a buy, sell or hold?

SIGA Technologies has no consensus analysts rating.

What are the forecasts/targets for the SIGA price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	17.5	210.3%
Analysts Target Price	17.5	210.3%

SIGA Fundamental Data Overview March 08, 2026

P/E Trailing = 6.1053
P/E Forward = 4.1322
P/S = 2.4113
P/B = 2.1961
P/EG = 3.3673
Revenue TTM = 172.2m USD
EBIT TTM = 93.7m USD
EBITDA TTM = 94.3m USD
Long Term Debt = 583k USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 583k USD (from shortTermDebt, last quarter)
Debt = 915k USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -171.0m USD (from netDebt column, last quarter)
Enterprise Value = 244.3m USD (415.3m + Debt 915k - CCE 172.0m)
Interest Coverage Ratio = -29.47 (Ebit TTM 93.7m / Interest Expense TTM -3.18m)
EV/FCF = 2.10x (Enterprise Value 244.3m / FCF TTM 116.3m)
FCF Yield = 47.61% (FCF TTM 116.3m / Enterprise Value 244.3m)
FCF Margin = 67.52% (FCF TTM 116.3m / Revenue TTM 172.2m)
Net Margin = 43.23% (Net Income TTM 74.5m / Revenue TTM 172.2m)
Gross Margin = 76.29% ((Revenue TTM 172.2m - Cost of Revenue TTM 40.8m) / Revenue TTM)
Gross Margin QoQ = 61.75% (prev 68.50%)
Tobins Q-Ratio = 1.05 (Enterprise Value 244.3m / Total Assets 231.6m)
Interest Expense / Debt = 97.38% (Interest Expense 891k / Debt 915k)
Taxrate = 22.16% (16.9m / 76.1m)
NOPAT = 73.0m (EBIT 93.7m * (1 - 22.16%))
Current Ratio = 9.17 (Total Current Assets 227.7m / Total Current Liabilities 24.8m)
Debt / Equity = 0.00 (Debt 915k / totalStockholderEquity, last quarter 203.5m)
Debt / EBITDA = -1.81 (Net Debt -171.0m / EBITDA 94.3m)
Debt / FCF = -1.47 (Net Debt -171.0m / FCF TTM 116.3m)
Total Stockholder Equity = 211.2m (last 4 quarters mean from totalStockholderEquity)
RoA = 34.88% (Net Income 74.5m / Total Assets 231.6m)
RoE = 35.26% (Net Income TTM 74.5m / Total Stockholder Equity 211.2m)
RoCE = 44.27% (EBIT 93.7m / Capital Employed (Equity 211.2m + L.T.Debt 583k))
RoIC = 34.55% (NOPAT 73.0m / Invested Capital 211.2m)
WACC = 9.14% (E(415.3m)/V(416.3m) * Re(9.16%) + (debt cost/tax rate unavailable))
Discount Rate = 9.16% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -81.65 | Cagr: -1.36%
[DCF] Terminal Value 77.65% ; FCFF base≈98.4m ; Y1≈121.3m ; Y5≈206.7m
[DCF] Fair Price = 41.97 (EV 2.83b - Net Debt -171.0m = Equity 3.01b / Shares 71.6m; r=9.14% [WACC]; 5y FCF grow 25.0% → 2.90% )
EPS Correlation: 7.30 | EPS CAGR: 3.13% | SUE: 0.0 | # QB: 0
Revenue Correlation: -24.84 | Revenue CAGR: -63.55% | SUE: 0.44 | # QB: 0
EPS next Year (2026-12-31): EPS=1.51 | Chg7d=-0.080 | Chg30d=-0.080 | Revisions Net=-1 | Growth EPS=+297.4% | Growth Revenue=+132.4%

Additional Sources for SIGA Stock

Fund Manager Positions: Dataroma | Stockcircle